Synthesis and biological evaluation of chalcone fused quinoline derivatives as anticancer agents
- 23 May 2019
- journal article
- research article
- Published by Elsevier BV in Chemical Data Collections
- Vol. 22, 100236
- https://doi.org/10.1016/j.cdc.2019.100236
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- Novel chalcones and 1,3,5‐triphenyl‐2‐pyrazoline derivatives as antibacterial agentsChemical Biology & Drug Design, 2010
- Synthesis and biological evaluation of a series of tangeretin-derived chalconesBioorganic & Medicinal Chemistry Letters, 2009
- Structure–activity relationship of antibacterial chalconesBioorganic & Medicinal Chemistry, 2008
- Antifungal activity of chalcones: A mechanistic study using various yeast strainsEuropean Journal of Medicinal Chemistry, 2008
- Synthesis, Cytotoxicity, and Anti-Trypanosoma cruzi Activity of New ChalconesJournal of Medicinal Chemistry, 2008
- A review of anti-infective and anti-inflammatory chalconesEuropean Journal of Medicinal Chemistry, 2007
- Chalcones as potent tyrosinase inhibitors: the effect of hydroxyl positions and numbersPhytochemistry, 2004
- Linker-modified quinoline derivatives targeting HIV-1 integrase: synthesis and biological activityBioorganic & Medicinal Chemistry Letters, 2004
- A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline DerivativesJournal of Medicinal Chemistry, 1994